Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period
Time Perspective: Retrospective and Prospective
Observational
Observational Model: Cohort
Incidence of Malignancy (All malignancy collected)
January 2000 - December 2014
Yes
Medical Monitor
Study Director
Merck
Denmark: Danish Medicines Agency
0518-058
NCT01078233
May 2008
December 2014
Name | Location |
---|